Clinical trial
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib…
NCT00401843 · Janssen Research & Development, LLC, Industry · Completed
Key facts
| NCT number | NCT00401843 |
|---|---|
| Title | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade Versus Velcade Alone in Subjects With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Biological, Drug |
| Interventions | Siltuximab, Bortezomib, Placebo, Dexamethasone |
| Enrollment | 307 |
| Start date | Nov 28, 2006 |
| Primary completion | Aug 16, 2011 |
| Completion | Sep 24, 2019 |
| First posted | Nov 22, 2006 |
| Last update posted | Nov 19, 2019 |
| Countries | Belgium, Brazil, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Netherlands, Poland, Portugal and 6 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: